first-in-class membrane lipid modulator.

LAU-7b is a proprietary oral drug candidate based on fenretinide, an atypical retinoid (vitamin A derivative), with a well-documented safety profile established in more than 3,000 patients. Existing data suggest that low-dose fenretinide has the potential to modulate certain membrane lipids and exerts antiviral, inflammation-controlling, and antifibrotic properties.

Membrane lipids

a balancing act.

Lipids are fundamental cell components responsible for cell membrane structure, fluidity, and function. Membrane lipids play multiple biological roles ranging from first-line host defense against pathogens, to inflammation signaling and protein trafficking. Their potential as therapeutic targets remain largely untapped.

Low-dose LAU-7b focuses on certain phospholipids and sphingolipids that play central roles in the activation/resolution of the inflammation process, as well as in the host defense against pathogens.

Proposed mode of action for LAU-7b lipid modulation

LAU-7b’s lipid-modulating mechanism follows a multitarget pharmacology involving desaturases (delta-4 and delta-9) and ceramide synthase (CerS5), all of which playing important roles in fatty acid metabolism. LAU-7b activity was also associated with the modulation of cPLA2, ERK 1/2 and NF-κB inflammation signaling pathways.


the inflammation “off switch”.

LAU-7b was shown to increase phospholipids linked to docosahexaenoic acid (DHA) involved in the resolution phase of inflammation, and indirectly having a downregulating effect on the arachidonic acid (AA) pathway responsible for the inflammation activation process. The balancing effect on DHA/AA mimics body’s own inflammation-controlling process (a “pro-resolving” effect). 


Garic D. et al, 2020. Cellular and Molecular Life Sciences.
Garic D. et al, 2020. Journal of Molecular Medicine.
Youssef M. et al, 2021. Lung.
Poliakov E. et al, 2017. PLoS ONE.
Rodriguez-Cuenca S. et al, 2016. PLoS ONE.
Rodriguez-Cuenca S. et al, 2015. Biochimica et Biophysica Acta.